# Amneal jumps 6.4% on Barclays upgrade

> Barclays raises its price target on the drugmaker by 25%, signaling confidence in the company's near-term prospects.
- Title: Amneal jumps 6.4% on Barclays upgrade | Shortify
- Summary: Barclays raises its price target on the drugmaker by 25%, signaling confidence in the company's near-term prospects. Analyst upgrades can drive significant…
- Keywords: amneal pharmaceuticals, amrx, barclays, stock upgrade, price target increase, pharmaceutical stocks, wall street analyst, specialty drugs, generic drugs, mid-cap stocks, Amneal, jumps
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/amneal-pharmaceuticals-jumps-6-4-after-barclays-maintains-overweight
- Author: AlphaStreet Newsdesk
- Published: 2026-09-21T15:36:30+00:00
- Read time: 1 min
- Topics: amneal pharmaceuticals, amrx, barclays, stock upgrade, price target increase, pharmaceutical stocks, wall street analyst, specialty drugs, generic drugs, mid-cap stocks
## Barclays upgrades Amneal to overweight
The analyst elevated Amneal Pharmaceuticals to Overweight and raised its price target from $16 to $20, a 25% increase signaling growing confidence in the drugmaker's trajectory.
## Stock jumps 6.4% on the news
Amneal climbed to $19.90 on Monday with 1.0M shares traded as the analyst action sparked buying interest in the $7.2B pharmaceutical company.
## New target sits just above current price
The $20 price target sits just above Monday's closing price of $19.90, suggesting Barclays sees modest near-term upside from current levels.
## Mid-cap positioning attracts institutional interest
Amneal's $7.2B market cap positions it as a mid-sized player where analyst commentary can move shares significantly as institutional investors reassess positioning.
## Watch for follow-up analyst moves
Investors should monitor whether additional analysts follow Barclays' lead with upgrades, and watch for company commentary on pipeline developments that may have informed the bullish revision.
## Key takeaway

Analyst upgrades can drive significant single-day moves in mid-cap pharmaceutical stocks, especially when paired with meaningful price target increases.